Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), heart failure treatment with sacubitril/valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared with enalapril but resulted in more symptomatic hypotension. Concern on hypotension may be limiting use of sacubitril/valsartan in appropriate patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circ Heart Fail

Title: Circulation. Heart failure

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1941-3297

ISSN (Print): 1941-3289

Publication date (Electronic): Apr 2018

Volume: 11

Issue: 4

Affiliations

[1 ] Minneapolis VA Health Care System and University of Minnesota (O.V.). University of Colorado, Aurora (S.M.P.). Brigham and Women's Hospital, Harvard University, Boston, MA (B.C., A.S.D., S.D.S.). Novartis Pharmaceuticals Corporation, East Hanover, NJ (J.K., M.L., V.S.). University of Glasgow, United Kingdom (J.J.V.M.). Baylor University Medical Center, Dallas, TX (M.P.). Université de Montréal, Canada (J.R.). Medical University of South Carolina, Charleston (M.R.Z.). University of Gothenburg, Sweden (K.S.).

[2 ] Minneapolis VA Health Care System and University of Minnesota (O.V.). University of Colorado, Aurora (S.M.P.). Brigham and Women's Hospital, Harvard University, Boston, MA (B.C., A.S.D., S.D.S.). Novartis Pharmaceuticals Corporation, East Hanover, NJ (J.K., M.L., V.S.). University of Glasgow, United Kingdom (J.J.V.M.). Baylor University Medical Center, Dallas, TX (M.P.). Université de Montréal, Canada (J.R.). Medical University of South Carolina, Charleston (M.R.Z.). University of Gothenburg, Sweden (K.S.). ssolomon@bwh.harvard.edu.

Article

Publisher Item ID: CIRCHEARTFAILURE.117.004745

DOI: 10.1161/CIRCHEARTFAILURE.117.004745

PubMed ID: 29643067

SO-VID: 26fc6f21-0302-4727-9035-2795ae1c141b

History

Keywords: angiotensin-converting enzyme inhibitors,pharmacology,hypotension,heart failure,blood pressure

Data availability:

Keywords: angiotensin-converting enzyme inhibitors, pharmacology, hypotension, heart failure, blood pressure

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 112

Cited by 27